Y-Intercept (HK)’s Lineage Cell Therapeutics LCTX Stock Holding History

Y-Intercept (HK)’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-405,043	Closed	-$368K	–	1817
2025 Q2	$368K	Buy	+405,043	New	+$240K	0.01%	1301
2023 Q2	–	Sell	-66,298	Closed	-$99.4K	–	1525
2023 Q1	$99.4K	Buy	+66,298	New	+$92.5K	0.01%	1056
2022 Q3	–	Sell	-44,829	Closed	-$71K	–	1135
2022 Q2	$71K	Buy	+44,829	New	+$59.1K	0.01%	736

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Y-Intercept (HK)'s LCTX Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 405,043 shares — an estimated $368K sold.

Y-Intercept (HK) first reported a position in LCTX in Q2 2022 and held it in 3 quarters. The position peaked at $368K in Q2 2025. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

Y-Intercept (HK) reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 405,043 Lineage Cell Therapeutics shares in Q3 2025, an estimated $368K.
Y-Intercept (HK) first reported a position in Lineage Cell Therapeutics in Q2 2022 and held it in 3 quarters.
Y-Intercept (HK)'s Lineage Cell Therapeutics position peaked at $368K in Q2 2025.
112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.